Clinical Trial Update: A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating BIIB105 in amyotrophic lateral sclerosis (including participants with the ATXN2 genetic mutation) was terminated. Results from the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• BIIB105

Snippet

Sponsor: Biogen | Conditions: Amyotrophic Lateral Sclerosis | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2025-10-09